Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow‐up of a multicenter, retrospective real‐world experience with 321 cases outside of controlled clinical trials

Enrica Antonia Martino, Pellegrino Musto, Mónica Galli et al.|Hematological Oncology|2024

Cited by 7